Seems that Omontys should have remained on the Market with enforced warnings regarding allergic reactions. Seems the 3 deaths at the Fresenius Centers should have been investigated as part of the on going investigation of other deaths at the Center which were covered up resulting in on going lawsuits there. Seems to me no other deaths would have been reported being the drug is safe and effective?
Ive researched the history of the recall, etc and I am of the came conclusion.
I also suspect Fresenius, Takeda, and AFFY thought it may be better long term to do the voluntary before more damage was done, but it provided some cover (at that time) of slack supv @fresenius centers. I think they all hv a plan to re-introduce omontys, with lable changed, more protocol supv, etc.
And all these patients are "chronic" -so if not omontys, what else? Something better? Probably not.. Also note no issues noted when administered subcutaneously.. Little risk vs. HUGE rewards...
Sentiment: Strong Buy
One month later, I still see people repeating the same boring things. That was when the stock had a 1.50$ value. And people are still talking about Omontys, Takeda, a buyout. We are passed mid-June and things have only got worse. Stop wasting your time and money and let it go.
We all know pulling Omontys off the Market so quickly is nothing less than suspect. Then factor in Affy's x-CEO Mr. Orwin driving the pps into the ground to only then return to Affy as Chairman of the Board, smacks of a Buyout!!